Activation of CD36 inhibits and induces regression of inflammatory corneal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 10, 2006, Pages 4356-4364

  Mwaikambo, Bupe R ^a,b   Sennlaub, Florian ^c   Ong, Huy ^d   Chemtob, Sylvain ^a,b   Hardy, Pierre ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c INSERM   (France)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 PALMITOYL 2 (5' OXOVALEROYL)PHOSPHATIDYLCHOLINE; ANTIBODY; CD31 ANTIGEN; CD36 ANTIGEN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; 1 PALMITOYL 2 (5 OXOVALEROYL) SN GLYCERO 3 PHOSPHORYLCHOLINE; 1-PALMITOYL-2-(5-OXOVALEROYL)-SN-GLYCERO-3-PHOSPHORYLCHOLINE; ETHER PHOSPHOLIPID; LOW DENSITY LIPOPROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA NEOVASCULARIZATION; ENDOTHELIUM CELL; IMMUNOFLUORESCENCE; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR RING; ANIMAL; C57BL MOUSE; CORNEA; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; INJURY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD36; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; PHOSPHOLIPID ETHERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOSPONDIN 1; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33750576411     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1656     Document Type: Article

References (50)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-224.
2. Dana MR, Streilin JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37:2485-2394.
3. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285:245-248.
4. Spranger J, Hammes HP, Preissner KT, Schatz H, Pfeiffer AF. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation. Diabetologia. 2000;43:1404-1407.
5. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511.
6. Ambati BK, Joussen AM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002;120:1063-1068.
7. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000;6:196-199.
8. Lin HC, Chang JH, Jain S, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001;42:2517-2524.
9. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1997;39:18-22.
10. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 2003;44:117-123.
11. Polverini PJ, Cotran PS, Gimbrone MAJr, Unanue ER. Activated macrophages induce vascular proliferation. Nature. 1977;269:804-806.
12. Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, ad Van der Gaag R. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci. 1994;35:3505-3515.
13. Asch A, Barnwell J, Silverstein R, Nachman R. Isolation of the thrombospondin membrane receptor. J Clin Invest. 1987;79:1054-1061.
14. Greenwalt D, Lipsky R, Ockenhouse C, Ikeda H, Tandon N, Jamieson G. Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood. 1992;80:1105-1115.
15. Dawson DW, Pearce SFA, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial Cells. J Cell Biol. 1997;138:707-717.
16. Cursiefen C, Masli S, Ng TF, Dana MR, Bornstein P, Lawler J, Streilein JW. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.
17. Endemann G, Stanton LW, Madden KS, Bryant K, White RT, Protter A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem. 1993;268:11811-11816.
18. Nicholson A, Pearce SFA, Silverstein R. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscl Thromb 1995;15:269-275.
19. Boullier A, Gillotte KL, Horkko S, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000;275:9163-9169.
20. Podrez EA, Poliakov E, Shen Z, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD56.J Biol Chem. 2002;277:38503-38516.
21. Podrez EA, Hoppe G, O'Neil J, Hoff HF. Phospholipids in oxidized LDL not adducted to apoB are recognized by the CD36 scavenger receptor. Free Radic Biol Med. 2003;34:356-364.
22. Boullier A, Friedman P, Harkewicz R, et al. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res. 2005;46:969-976.
23. Barnwell J, Ockenhouse C, Knowles D. Monoclonal antibody OKM5 inhibits the in vitro binding of Plasmodium falciparum infected erythrocytes to monocytes, endothelial, and C32 melanoma cells. J Immunol. 1985;135:3464-3467.
24. Tandon N, Kralisz U, Jamieson G. Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem. 1989;264:7576-7583
25. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785-791.
26. Ryeom SW, Silverstein RL, Scotto A, Sparrow JR. Binding of anionic phospholipids to retinal pigment epithelium may be mediated by the scavenger receptor CD36. J Biol Chem. 1996;271:20536-20539
27. Baudouin C, Brignole F, Pisella PJ, Becquet F, Philip PJ. Immunophenotyping of human dendriform cells from the conjunctival epithelium. Curr Eye Res. 1997;16:475-481.
28. Finnemann SC, Silverstein RL. Differential roles of CD36 and alphavbeta5 integrin in photoreceptor phagocytosis by the retinal pigment epithelium. J Exp Med. 2001;194:1289-1298.
29. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6:41-48.
30. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation. 2003;108:198-204.
31. Kermorvant-Duchemin E, Sennlaub F, Sirinyan M, et al. Transarachidonic acids generated during nitrative stress induce a thrombospondin-1-dependent microvascular degeneration. Nat Med. 2005;11:1339-1345.
32. Masson VV, Devy L, Grignet-Debrus C, et al. Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis. Biol Proc Online. 2002;4:24-31.
33. Brissette-Storkus CS, Reynolds SM, Lepisto AJ, Hendricks RL. Identification of a novel macrophage population in the normal mouse corneal stroma. Invest Ophthalmol Vis Sci. 2002;43:2264-2271.
34. Lahaie I, Hardy P, Hou X, et al. A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels. Am J Physiol. 1998;274:R1406-R1416.
35. Zhu SN, Dana MR. Expression of cell adhesion molecules on limbal and neovascular endothelium in corneal inflammatory neovascularization. Invest Ophthalmol Vis Sci. 1999;40:1427-1434.
36. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. Corneal neovascularization: pathogenesis and inhibition. Cornea. 1987;6:250-257.
37. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040-1050.
38. Xiong M, Elson G, Legarda D, Leibovich SJ. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am J Pathol. 1998;153:587-598.
39. Jimenez B, Volpert OV, Reiher F, et al. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1. Oncogene 2001;20:3443-3448.
40. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140-4145.
41. Primo L, Ferrandi C, Roca C, et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J. 2005;19:1713-1715.
42. Huang MM, Bolen JB, Barnwell JW, Shattil SJ, Brugge JS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci USA. 1991;88:7844-7848.
43. Poulaki V, Mitsiades N, Kruse FE, et al. Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression. Am J Pathol. 2004;164:1293-1302.
44. Surace EM, Balaggan KS, Tessitore A, et al. Inhibition of ocular neovascularization by hedgehog blockade. Mol Ther. 2006;13:573-579.
45. Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1. J Clin Invest. 2001;107:45-52.
46. Primbs GB, Casey R, Wamser K, Snyder Wf, Crean DH. Photodynamic therapy for corneal neovascularization. Ophthalmol Surg Lasers. 1998;29:832-838.
47. Modlich U, Kaup FJ, Augustin HG. Cyclic angiogenesis and blood vessel regression in the ovary: blood vessel regression during luteolysis involves endothelial cell detachment and vessel occlusion. Lab Invest. 1996;74:771-780.
48. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factors withdrawal. J Clin Invest 1999;103:159-165.
49. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest. 1998;78:1385-1394.
50. Hiscott P, Seitz B, Schlotzer-Schrehardt U, Naumann GO. Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res. 1997;289:307-310.